SCHEMBL20208922

SCHEMBL20208922

BrCC#Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.54
CYP1A1 P04798 1/20 0.54
CYP1B1 Q16678 1/20 0.54
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
THPO P40225 1/20 0.45
KCNH2 Q12809 1/20 0.44
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
ALDH1A1 P00352 3/20 0.41
MAPK1 P28482 1/20 0.41
APP P05067 1/20 0.40
PTPN1 P18031 1/20 0.39
GSK3B P49841 1/20 0.39
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
GRM5 P41594 2/20 0.39
HTR2A P28223 1/20 0.38
SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2176081 0.91 CHRNA7 (0.40) CYP1A2CYP1A1CYP1B1CYP3A4CYP2C9
SCHEMBL1151193 0.86 CYP1A2 (0.58) CYP1A2CYP3A4CYP2C9CYP2C19THPO
SCHEMBL14984807 0.81 MMP3 (0.48) APPPTPN1MMP2MEN1KMT2A
SCHEMBL14346735 0.81 TRPA1 (0.36) CYP1A2CYP1A1CYP1B1CYP3A4CYP2C9
SCHEMBL3348718 0.80 CYP1A2 (0.47) CYP1A2CYP1A1CYP1B1CYP3A4CYP2C9
SCHEMBL80946 0.78 CYP1A2 (0.54) CYP1A2CYP1A1CYP1B1CYP3A4CYP2C9
SCHEMBL27402182 0.78 CYP1A2 (0.59) CYP1A2CYP1A1CYP1B1CYP3A4CYP2C9
SCHEMBL6304104 0.78 LTA4H (0.47) MMP2MMP13GRM5ACACB
SCHEMBL9638565 0.77 CYP1A2 (0.52) CYP1A2CYP1A1CYP1B1CYP3A4CYP2C9
SCHEMBL5886608 0.76 APP (0.71) CYP1A2CYP1A1CYP1B1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023229295-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING PHENYLPROPENE DERIVATIVE AS ACTIVE INGREDIENT 재단법인 대구경북첨단의료산업진흥재단 2023-11-30 WO disclosed
CN-108101826-B Indole-substituted alkylamine compound and application thereof 华东理工大学 2022-05-10 CN disclosed
US-10829464-B2 Benzoheterocyclic alkylamine compounds and use thereof EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2020-11-10 US disclosed
US-20190315703-A1 BENZOHETEROCYCLIC ALKYLAMINE COMPOUNDS AND USE THEREOF EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2019-10-17 US disclosed
WO-2018095287-A1 BENZOHETEROCYCLYL ALKYLAMINE COMPOUND AND USE THEREOF 华东理工大学 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10829464-B2 Benzoheterocyclic alkylamine compounds and use thereof AADAC, AAAS, NISCH CYP1A2 1004/4885CYP1A1 1450/4885CYP1B1 347/4885
US-20190315703-A1 BENZOHETEROCYCLIC ALKYLAMINE COMPOUNDS AND USE THEREOF AADAC, AAAS, NISCH CYP1A2 1004/4885CYP1A1 1450/4885CYP1B1 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.